FDA Determines Regulatory Review Period for XPOVIO Patent Extension Application

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for XPOVIO, a human drug product, following a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO). This determination is being published as required by law.